Table 2.

Possible drug interactions between DAAs and immunosuppressive drugs

	Elbasvir/grazoprevir	Ombitasvir/paritaprevir/ribavirin	Ombitasvir/paritaprevir/ribavirin/dasabuvir	Simeprevir	Sofosbuvir/velpatasvir/voxilaprevir	Daclatasvir	Glecaprevir/pibrentasvir	Ledipasvir/sofosbuvir	Sofosbuvir/velpatasvir	Sofosbuvir
CSA	Increase grazoprevir AUC by 15-fold	Increase CSA AUC by 4-fold, increase paritaprevir 46%	Increase CSA AUC by 5.8fold	Increase simeprevir AUC by 5.81-fold	Concentration of voxilaprevir increase by 19-fold	(-)	Not recommended for patients requiring CSA doses >100 mg/day	(-)	(-)	(-)
TAC	Increase TAC AUC by 43%	Increase TAC AUC by 86-fold	Increase TAC AUC by 57fold	Increase simeprevir AUC by 85%,
Decrease TAC AUC by 17%	Increase TAC AUC by 9%, increase sofosbuvir AUC by 13%		Increase TAC AUC by 1.45fold
AZA	(-)	(-)		(-)	(-)	(-)		(-)	(-)	(-)
MMF	(-)	Unknown	Unknown	(-)	(-)	(-)	(-)	(-)	(-)	(-)
SRL	Unknown	Increase SRL AUC by 38-fold	Increase SRL AUC by 38fold	Unknown	Unknown	(-)	Unknown	(-)	(-)	(-)
EVR	Unknown	Increase EVR AUC by 27.1fold	Increase EVR AUC by 27.1fold	Unknown	Unknown	May increase EVR concen tration	Unknown	May increase EVR concen tration	Unknown	(-)

CSA, cyclosporine A; TAC, tacrolimus; AZA, azathioprine; MMF, mycophenolate mofetyl; SRL, sirolimus; EVR, everolimus; AUC, area under the plasma drug concentration-time curve (reflects the actual body exposure to drug after administration of a dose of the drug) (https://www.hep-druginteractions.org)